PORCINE SAPOVIRUS
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Difficult: Clinical signs not unique and test(s) not available at local/regional laboratory; Minor: Low prevalence, typically non-lethal infection with recovery very likely; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
OVERVIEW
Porcine sapoviruses are common enteric caliciviruses of pigs and are more clearly associated with diarrhea than porcine noroviruses. Infection occurs early in life and is widespread globally. Disease is usually mild to moderate and self-limiting, with limited production impact.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
There is no evidence that porcine sapoviruses infect humans via pork consumption.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
Despite genetic relatedness to human sapoviruses, no evidence supports routine zoonotic transmission.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
Fecal–oral transmission with environmental persistence is important. Wildlife reservoirs have been identified, but pig-associated pathways dominate.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Difficult: Clinical signs not unique and test(s) not available at local/regional laboratory
Diagnostics are primarily research-based (RT-PCR, EM). Routine field confirmation is uncommon and sensitivity is not fully characterised.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Minor: Low prevalence, typically non-lethal infection with recovery very likely
Clinical disease is generally mild and transient. Outbreaks rarely result in sustained or severe economic loss.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
Sapoviruses are not trade-limiting and do not affect consumer confidence.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
Viral pathogen with no AMR relevance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
Management does not drive antimicrobial use.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
Treatment is supportive only.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
No vaccines are available.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Difficult and uncertain: Extremely difficult and with uncertain success rate, few global examples of success even at farm level
High prevalence, environmental persistence, and limited impact make eradication infeasible.